AdjuTec Pharma Overview
- Year Founded
-
2019
- Status
-
Private
- Employees
-
8
- Latest Deal Type
-
Accelerator/Inc
- Investors
-
6
AdjuTec Pharma General Information
Description
Developer of antibiotic resistance breakers is designed to meet the imminent threat to modern medicine of antimicrobial resistance. The company's technology is a synthesis of β-lactamase inhibitors that inactivate bacteria's resistance enzymes by taking down bacteria's defense, enabling researchers to preserve the susceptibility of broad-spectrum antibiotics.
Contact Information
Website
www.adjutecpharma.comCorporate Office
- Gaustadalléen 21
- 0349 Oslo
- Norway
Corporate Office
- Gaustadalléen 21
- 0349 Oslo
- Norway
AdjuTec Pharma Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Accelerator/Incubator | Completed | Pre-Clinical Trials | ||||
| 3. Early Stage VC | 01-Feb-2023 | Completed | Pre-Clinical Trials | |||
| 2. Grant | 20-Jun-2022 | $1.24M | Completed | Pre-Clinical Trials | ||
| 1. Early Stage VC | 01-Jan-2021 | Completed | Pre-Clinical Trials |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
AdjuTec Pharma Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
AdjuTec Pharma Patents
AdjuTec Pharma Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026104587-A1 | Cyclic boronic acid esters useful as adjuvants in the treatment of bacterial infections | Pending | 13-Nov-2024 | ||
| GB-202416724-D0 | Therapy | Inactive | 13-Nov-2024 | ||
| GB-202416728-D0 | Therapy | Inactive | 13-Nov-2024 | ||
| WO-2024231518-A1 | Combination therapy for bacterial infections comprising zinc-chelator, beta-lactam antibiotic and cyclic boronate beta-lactamase inhibitor | Inactive | 09-May-2023 | ||
| EP-4712972-A1 | Combination therapy for bacterial infections comprising zinc-chelator, beta-lactam antibiotic and serine beta-lactamase inhibitor | Pending | 09-May-2023 | A61K45/06 |
AdjuTec Pharma Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
AdjuTec Pharma Investors (6)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Farvatn Venture | Venture Capital | Minority | ||
| Kistefos | PE/Buyout | Minority | ||
| Eurostars | Other | Minority | ||
| Norwegian Research Council | Government | |||
| Radforsk Investeringsstiftelse | Venture Capital | Minority |
AdjuTec Pharma FAQs
-
When was AdjuTec Pharma founded?
AdjuTec Pharma was founded in 2019.
-
Where is AdjuTec Pharma headquartered?
AdjuTec Pharma is headquartered in Oslo, Norway.
-
What is the size of AdjuTec Pharma?
AdjuTec Pharma has 8 total employees.
-
What industry is AdjuTec Pharma in?
AdjuTec Pharma’s primary industry is Drug Discovery.
-
Is AdjuTec Pharma a private or public company?
AdjuTec Pharma is a Private company.
-
What is AdjuTec Pharma’s current revenue?
The current revenue for AdjuTec Pharma is .
-
Who are AdjuTec Pharma’s investors?
Farvatn Venture, Kistefos, Eurostars, Norwegian Research Council, and Radforsk Investeringsstiftelse are 5 of 6 investors who have invested in AdjuTec Pharma.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
